indice level for underwritting being cancelled, page-4

I agree. Calling them management is complimentary. These guys have burnt everyone, not just Baker Young, but Novus, Retirewell, long term investors $3 amd $6, short term investors in the float at $1. They don't put their own in, they just churn it and pay themselves handsomely. This drug should have well and truly been commercialized by now if it hadn't been for poor decisions and lack of necessary pharma knowledge 6 years ago. They thought they had a drug worth billions after trialling it an about 20 people with an incomplete patchwork of patents worth almost nothing. A big pharma actually went to the expense of sending a team of 20 people out from England only to to discover a myriad of shortcomings.
This is a good drug,unfortunately,it's been badly mishandled. It's now just one dilution after another at unrealistically discounted prices ( given that the drug is closer than ever to commercialization).